Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26312140 | 0.94 | CASP3 (0.47) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL24580478 | 0.94 | CASP3 (0.47) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL30640767 | 0.94 | CASP3 (0.47) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL24580479 | 0.91 | CASP3 (0.45) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL29696679 | 0.91 | CASP3 (0.47) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL29696649 | 0.90 | CASP3 (0.48) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL24579343 | 0.90 | CASP3 (0.42) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL30640779 | 0.90 | CASP3 (0.42) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL24579358 | 0.89 | CASP3 (0.51) | CASP3CTSLCTSBCTSSCTSK | |
| SCHEMBL24579290 | 0.88 | CASP3 (0.41) | CASP3CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| CN-116615411-A | Process for producing peptide compound containing N-substituted amino acid residue | 中外制药株式会社 | 2023-08-18 | — | — | CN | disclosed |
| EP-4144747-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698032-A | Efficient peptide condensation of difficult sequences | 中外制药株式会社 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | CASP3 3884/4885CTSL 859/4885CTSB 1455/4885 |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | CASP3 4334/4885CTSL 1225/4885CTSB 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.